Case Studies

Driven by a focus on the cytokine TNF-like protein 1A (TL1A) and a strong patient database, Prometheus Biosciences, Inc. (NASDAQ:RXDX) advanced its lead drug PRA023 to treat ulcerative colitis and…

Tricida, Inc. (NASDAQ:TCDA) liquidated in June 2023 after its drug veverimer experienced a wild ride in the previous three years. The company designed veverimer to prevent the onset of metabolic…

With its lead asset FYARRO (nab-Sirolimus) already approved to treat the rare cancer perivascular epithelioid cell neoplasm (PEComa), Aadi Bioscience, Inc. (NASDAQ:AADI) sought to expand the treatment to more common…

Advancing neuropsychiatric drugs to the market is loaded with risk. Measured steps are necessary. BioXcel Therapeutics decided to take on the indication by developing a sublingual thin film of the…

Acceleron Pharma traded slightly under the radar during 2019 as the company’s luspatercept partnership with Celgene was overlooked when challenges emerged to

Many cancers remain difficult to treat and bladder cancer is no exception. Urogen Pharma developed two formulations of the drug mitomycin, UGN-101 and UGN-102

While not as life threatening as cancer or HIV, narcolepsy remains a poorly treated condition that afflicts approximately 200,000 Americans and 3 million people

Dynavax’s (NASDAQ:DVAX) BLA application for its Hepatitis B vaccine first received a complete response letter from the FDA in 2013 and then experienced further regulatory delays between 2015-2016. Some of…

ARMO Biosciences (ARMO) listed in January 2018 at $17 per share. The company had a phase III pancreatic cancer drug in AMO010, a recombinant form of human interleukin 10 (IL-10). …

MyoKardia (NASDAQ:MYOK), a leading precision cardiovascular medicine company, reported good data during 2015-16 on its drug, mavacamten, to treat hypertrophic cardiomyopathy (HCM), a condition that reduces the rate of heart…